A Phase 2, multicenter, randomized, double-blind, placebo-controlled study

Recruiting

18 years - 80 years

All

Phase 2

7 participants needed

1 Location

Brief description of study

SAR443820 is a selective, orally bioavailable, central nervous system (CNS)-penetrant, receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor. The aim of this Phase 2 study is to determine the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SAR443820 in treating adult participants with amyotrophic lateral sclerosis (ALS).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Amyotrophic Lateral Sclerosis,ALS
Age: 18 years - 80 years
Gender: All

Male and Female patients between 18 and 80 years of age; confirmed ALS diagnosis; less than 2 years since symptom onset; no history of seizures/epilepsy; no significant cognitive impairment; no PICC or port-a-cath lines.

Updated on 04 Aug 2024. Study ID: 850960

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an open-label extension

Brief description of study

Eligibility of study

Find a site

Interested in the study